Introducing LGSOC
Diagnosis
Management
Emerging Treatments
Resources
Sign Up

Confirmation Popup

This information is for US Healthcare Professionals.

Please confirm that you are a U.S. Healthcare Professional

Posted

November 1, 2023

in

by

lookwhat-admin

Tags:

References

Matsuo K, Machida H, et al. Trends of low-grade serous ovarian carcinoma in the United States. J Gynecol Oncol. 2018;29(1):e15. doi: 10.3802/jgo.2018.29.e15.
Babaier A, Mal H, Alselwi W, Ghatage P. Low-Grade Serous Carcinoma of the Ovary: The Current Status. Diagnostics (Basel). 2022 Feb 10;12(2):458. doi: 10.3390/diagnostics12020458. PMID: 35204549; PMCID: PMC8871133.
Grisham RN, Manning‐Geist BL, Chui MH. The highs and lows of serous ovarian cancer. Cancer. 2023;1‐8. doi:10.1002/cncr.34903
Zwimpfer TA, Tal O, Geissler F, Coelho R, Rimmer N, Jacob F, Heinzelmann-Schwarz V. Low grade serous ovarian cancer – A rare disease with increasing therapeutic options. Cancer Treat Rev. 2023 Jan;112:102497. doi: 10.1016/j.ctrv.2022.102497. Epub 2022 Dec 10. PMID: 36525716
Grisham RN, Slomovitz BM, Andrews N, et al. Low-grade serous ovarian cancer: Expert consensus report on the state of the science
Grabowski JP, Harter P, Heitz F, et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol. 2016;140:457-462. doi:10.1016/j.ygyno.2016.01.022
Schmeler KM, Sun CC, Bodurka DC, et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008;108:510-514. doi:10.1016/j.ygyno.2007.11.013
Harvard Health
Ovarian Cancer, Version 3.2.0.22. Featured Updates to the NCCN Guidelines. Natl Compr Canc Netw 2022;20(9):972–980 doi: 10.6004/jnccn.2022.0047
Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004 Apr;28(4):496-504. doi: 1097/00000478-200404000-00009. PMID: 15087669
Manning-Geist B, Gordhandas S, Liu YL, et al. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. Clin Cancer Res. 2022;28:4456-4465. doi:10.1158/1078-0432.CCR-21-4183

Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16(5):267-282. doi:10.1097/PAP.0b013e3181b4fffa
Babaier A, Mal H, Alselwi W, Ghatage P. Low-grade serous carcinoma of the ovary: The current status. Diagnostics (Basel). 2022;12(2):458. doi:10.3390/diagnostics12020458
Ali RH, Kalloger SE, Santos JL, et al. Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry. Int J Gynecol Pathol. 2013;32(6):529-535.
Grabowski JP, Harter P, Heitz F, et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol. 2016;140:457-462. doi:10.1016/j.ygyno.2016.01.022
Matsuo K, Machida H, Grubbs B, et al. Trends of low-grade serous ovarian carcinoma in the United States. J Gynecol Oncol. 2018;29(1):e15. doi:10.3802/jgo.2018.29.e15
Plaxe SC. Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol. 2008 Apr;198(4):459.e1-8; discussion 459.e8-9.doi: 10.1016/j.ajog.2008.01.035
Certain symptoms may be early signs of ovarian cancer. Harvard Health. January 20, 2017. Accessed August 7, 2023. https://www.health.harvard.edu/cancer/certain-symptoms-may-be-early-signs-of-ovarian-cancer
Gockley A, Melamed A, Bregar AJ, et al. Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. Obstet Gynecol. 2017;129:439-447. doi:10.1097/AOG.0000000000001867
Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28(4):496-504. doi:10.1097/00000478-200404000-00009
Alcid J, Shahin MS. Low-grade serous carcinoma of the ovary: A case series and literature review. Case Rep Images Oncology. 2018;4:100052Z10JA2018. doi:10.5348/100052Z10JA2018CS
Grisham RN, Slomovitz BM, Andrews N, et al. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Published on Aug 17, 2023. Int J Gynecol Cancer. 2023;33(9):1331-1344. doi:10.1136/ijgc-2023-004610
Slomovitz B, Gourley C, Carey MS, et al. Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 2020;156(3):715-725. doi:10.1016/j.ygyno.2019.12.033
Banerjee SN, Ring KL, Nieuwenhuysen EV, et al. Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) 6 defactinib in recurrent low-grade serous ovarian cancer (LGSOC). J Clin Oncol. 41. No 16_suppl (June 1, 2023) 5515-5515.
Manning-Geist B, Gordhandas S, Liu YL, et al. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. Clin Cancer Res. 2022;28:4456-4465. doi:10.1158/1078-0432.CCR-21-4183

Terms of Use
Copyright Statement
Privacy Policy
Contact Us

© 2023 Verastem, Inc. All Rights Reserved.

The Verastem Oncology name and logo are trademarks of Verastem, Inc. All other trademarks mentioned on this website are property of their respective owners.